Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to develop cutting-edge therapies and commercial products that improve quality of life. AIVITA has developed a next-generation, personalized cancer immunotherapy that primes the patient’s immune system to target tumor-initiating cells, the very cells which drive the growth and spread of the disease. Successive improvements in manufacturing at AIVITA have made this personalized treatment reliable, quick, and economical to produce. The Company is currently conducting three clinical studies investigating its platform immunotherapy in patients with ovarian cancer, glioblastoma and melanoma. AIVITA uses 100% of proceeds from the sale of its ROOT of SKIN™ skincare line to support the treatment of women with ovarian cancer.